MX393998B - Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial - Google Patents

Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial

Info

Publication number
MX393998B
MX393998B MX2019012051A MX2019012051A MX393998B MX 393998 B MX393998 B MX 393998B MX 2019012051 A MX2019012051 A MX 2019012051A MX 2019012051 A MX2019012051 A MX 2019012051A MX 393998 B MX393998 B MX 393998B
Authority
MX
Mexico
Prior art keywords
proteins
barrier function
treatment
therapeutic proteins
epithelial barrier
Prior art date
Application number
MX2019012051A
Other languages
English (en)
Spanish (es)
Other versions
MX2019012051A (es
Inventor
Andrew Whitman Goodyear
Andrew Wonhee Han
Karim Dabbagh
Michi Izumi Willcoxon
Stefanie Banas
Tarunmeet Gujral
Todd Zachary Desantis
Toshihiko Takeuchi
Ye Jin
Original Assignee
Genevive Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevive Inc filed Critical Genevive Inc
Publication of MX2019012051A publication Critical patent/MX2019012051A/es
Publication of MX393998B publication Critical patent/MX393998B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
MX2019012051A 2017-04-07 2018-04-06 Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial MX393998B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762482963P 2017-04-07 2017-04-07
US201762607706P 2017-12-19 2017-12-19
US201762611334P 2017-12-28 2017-12-28
PCT/US2018/026447 WO2018187682A1 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders

Publications (2)

Publication Number Publication Date
MX2019012051A MX2019012051A (es) 2020-02-12
MX393998B true MX393998B (es) 2025-03-24

Family

ID=63710147

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012051A MX393998B (es) 2017-04-07 2018-04-06 Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial
MX2022008842A MX2022008842A (es) 2017-04-07 2019-10-07 Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008842A MX2022008842A (es) 2017-04-07 2019-10-07 Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.

Country Status (12)

Country Link
US (3) US10251933B2 (https=)
EP (1) EP3606542A4 (https=)
JP (2) JP7789303B2 (https=)
KR (2) KR20200003821A (https=)
CN (1) CN110769844B (https=)
AU (2) AU2018248324B2 (https=)
CA (1) CA3059354A1 (https=)
IL (1) IL269853A (https=)
MX (2) MX393998B (https=)
SG (1) SG11201909334TA (https=)
TW (1) TWI797116B (https=)
WO (1) WO2018187682A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251933B2 (en) * 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
EP3773644A4 (en) * 2018-04-06 2021-06-02 Second Genome, Inc. PROTEINS FOR TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
CN113347983A (zh) * 2018-10-09 2021-09-03 第二基因组股份有限公司 用于递送有效治疗上皮屏障功能障碍的蛋白质的乳酸乳球菌表达系统
US20210079086A1 (en) * 2019-08-21 2021-03-18 Astrazeneca Collaboration Ventures, Llc Use of Brazikumab to Treat Crohn's Disease
US11666629B2 (en) * 2020-01-10 2023-06-06 National Taipei University Of Technology Peptide interacting with toll-like receptor 2 and the composition comprising the same
CN113773364B (zh) * 2021-08-25 2023-04-28 无锡市儿童医院 小分子肽及其制备方法和应用
CN120882418A (zh) * 2022-11-04 2025-10-31 MiNK治疗公司 B细胞成熟抗原(bcma)嵌合抗原受体不变自然杀伤t细胞及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
DK3061766T3 (da) * 2009-04-28 2020-03-16 Univ Vanderbilt Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose
GB201117313D0 (en) * 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
JP2014093482A (ja) 2012-11-06 2014-05-19 Toshiba Corp 固体撮像装置の製造方法および固体撮像装置
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015014973A2 (en) * 2013-07-31 2015-02-05 Institut National De La Recherche Agronomique Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions
WO2016203221A1 (en) * 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) * 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11174293B2 (en) 2017-06-02 2021-11-16 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders

Also Published As

Publication number Publication date
KR102903277B1 (ko) 2025-12-23
US20240066095A1 (en) 2024-02-29
US20180289770A1 (en) 2018-10-11
US20200148728A1 (en) 2020-05-14
AU2023202844A1 (en) 2023-07-06
CN110769844B (zh) 2025-01-21
US11207376B2 (en) 2021-12-28
CA3059354A1 (en) 2018-10-11
TW201841649A (zh) 2018-12-01
KR20230144097A (ko) 2023-10-13
EP3606542A1 (en) 2020-02-12
MX2019012051A (es) 2020-02-12
TWI797116B (zh) 2023-04-01
JP7789303B2 (ja) 2025-12-22
IL269853A (en) 2019-11-28
US10251933B2 (en) 2019-04-09
JP2020516615A (ja) 2020-06-11
JP2024037834A (ja) 2024-03-19
AU2018248324A1 (en) 2019-10-31
WO2018187682A1 (en) 2018-10-11
AU2018248324B2 (en) 2023-02-09
CN110769844A (zh) 2020-02-07
KR20200003821A (ko) 2020-01-10
SG11201909334TA (en) 2019-11-28
MX2022008842A (es) 2022-08-02
EP3606542A4 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
MX2025009223A (es) Agentes de union a clec9a y su uso
MX2017010336A (es) Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
MX2021002321A (es) Nuevos metodos.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
MY200087A (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
CR20200114A (es) Compuestos que contienen pirazolopirimidinona y sus usos
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
EA201800199A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
NZ799031A (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
WO2017087608A8 (en) Modulators of ror-gamma
WO2015112793A3 (en) Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
IN2012DN02645A (https=)
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP3502248A4 (en) ANTIBODIES AGAINST HMGB1 AND COMPOSITION THERE FOR TREATING OR PREVENTING MORBUS ALZHEIMER
EA201690659A1 (ru) Композиции аморфного магнийзамещенного фосфата кальция и их применение
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment